Drug intelligence / Profile preview

PNC1

Development stage: Preclinical
Lead developer: Lineage Cell Therapeutics
Modality: Stem Cell Therapies → Cell Therapies

Overview

PNC1 is a preclinical-stage cell therapy candidate being developed by Lineage Cell Therapeutics for the treatment of vision loss, specifically retinitis pigmentosa. The program utilizes human embryonic stem cell (hESC)-derived photoreceptor cells designed to replace damaged or lost cells in the retina. By transplanting functional photoreceptors, the therapy aims to restore or preserve visual function in patients suffering from degenerative retinal diseases. PNC1 is part of Lineage's broader ophthalmology portfolio, which also includes OpRegen, a cell therapy for dry age-related macular degeneration.

Beyond the preview

Go deeper on PNC1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PNC1.

Explore the full profile